α vβ 6 integrin expression is induced in the POET and Pten pc-/- mouse models of prostatic inflammation and prostatic adenocarcinoma

American Journal of Translational Research

Volumn 4, Issue 2, 2012, Pages 165-174

  Garlick, David S ^a   Li, Jing ^a   Sansoucy, Brian ^a   Wang, Tao ^a   Griffith, Leeanne ^g   FitzGerald, T J ^a   Butterfield, Julie ^a   Charbonneau, Bridget ^b   Violette, Shelia M ^c,d   Weinreb, Paul H ^d   Ratliff, Timothy L ^b   Liao, Chun Peng ^e   Roy Burman, Pradip ^e   Vietri, Michele ^a   Lian, Jane B ^a   Stein, Gary S ^a   Altieri, Dario C ^f   Languino, Lucia R ^g  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b PURDUE UNIVERSITY   (United States)

^c Stromedix   (United States)

^d BIOGEN   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f WISTAR INSTITUTE   (United States)

^g THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

v 6 integrin; Akt; Chronic inflammation; PIN lesion; Prostate cancer; TGF 1

Indexed keywords

ALPHAVBETA6 INTEGRIN; OVALBUMIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; EXPERIMENTAL MOUSE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INFLAMMATION; MALE; MOUSE; NONHUMAN; PROSTATE ADENOCARCINOMA; PROSTATE INFLAMMATION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE;

EID: 84860186166     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Breuss JM, Gallo J, DeLisser HM, Klimanskaya IV, Folkesson HG, Pittet JF, Nishimura SL, Aldape K, Landers DV, Carpenter W. Expression of the β6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling. J Cell Sci 1995; 108: 2241-2251.
2. 6 integrin in wound healing and cancer of the oral cavity. J Oral Pathol Med 2006; 35: 1-10.
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
4. Pomerantz M, Kantoff P. Advances in the treatment of prostate cancer. Annu Rev Med 2007; 58: 205-220.
5. Macarthur M, Hold GL, El-Omar EM. Inflammation and Cancer II. Role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancy. Am J Physiol Gastrointest Liver Physiol 2004; 286: G515-520.
6. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-867.
7. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007; 7: 256-269.
8. De Marzo AM, DeWeese TL, Platz EA, Meeker AK, Nakayama M, Epstein JI, Isaacs WB, Nelson WG. Pathological and molecular mechanisms of prostate carcinogenesis: implications for diagnosis, detection, prevention, and treatment. J Cell Biochem 2004; 91: 459-477.
9. Hynes RO. Cell adhesion: old and new questions. Trends Cell Biol 1999; 9: M33-37.
10. Humphries MJ, Newham P. The structure of cell -adhesion molecules. Trends Cell Biol 1998; 8: 78-83.
11. Alam N, Goel HL, Zarif MJ, Butterfield JE, Perkins HM, Sansoucy BG, Sawyer TK, Languino LR. The integrin-growth factor receptor duet. J Cell Physiol 2007; 213: 649-653.
12. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002; 110: 673-687.
13. Chen HC, Guan JL. Stimulation of phosphatidylinositol 3'-kinase association with focal adhesion kinase by platelet-derived growth factor. J Biol Chem 1994; 269: 31229-31233.
14. Manes T, Zheng DQ, Loftus J, Woodard AS, Marchisio PC, Languino LR. αvβ3 integrin expression upregulates cdc2 which modulates cell migration. J Cell Biol 2003; 164: 817-826.
15. Assoian RK, Schwartz MA. Coordinate signaling by integrins and receptor tyrosine kinases in the regulation of G1 phase cell-cycle progression. Curr Opin Genet Dev 2001; 11: 48-53.
16. Mizejewski GJ. Role of integrins in cancer: survey of expression patterns. Proc Soc Exp Biol Med 1999; 222: 124-138.
17. Goel HL, Li J, Kogan S, Languino LR. Integrins in prostate cancer progression. Endocr Relat Cancer 2008; 15: 657-664.
18. Sheppard D, Rozzo C, Starr L, Quaranta V, Erle DJ, Pytela R. Complete amino acid sequence of a novel integrin β subunit (β6) identified in epithelial cells using the polymerase chain reaction. J Biol Chem 1990; 265: 11502-11507.
19. Arend LJ, Smart AM, Briggs JP. Mouse β6 integrin sequence, pattern of expression, and role in kidney development. J Am Soc Nephrol 2000; 11: 2297-2305.
20. 6-mediated TGF-β activation causes Mmp12-dependent emphysema. Nature 2003; 422: 169-173.
21. 6 as a fibronectin-binding protein. J Biol Chem 1992; 267: 5790-5796.
22. Breuss JM, Gillett N, Lu L, Sheppard D, Pytela R. Restricted distribution of integrin β6 mRNA in primate epithelial tissues. J Histochem Cytochem 1993; 41: 1521-1527.
23. 6 integrin. J Invest Dermatol 1996; 106: 42-48.
24. 6 integrin and androgen receptor. IMPaCT Meeting, Proceedings, Atlanta, GA, September, 5-8, 2007.
25. Wu X, Wu J, Huang J, Powell WC, Zhang J, Matusik RJ, Sangiorgi FO, Maxson RE, Sucov HM, Roy-Burman P. Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev 2001; 101: 61-69
26. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, Thomas GV, Li G, Roy-Burman P, Nelson PS, Liu X, Wu H. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003; 4: 209-221.
27. Vlietstra RJ, van Alewijk DCJG, Hermans KGL, van Steenbrugge GJ, Trapman J. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res 1998; 58: 2720-2723.
28. Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman JG, Jen J, Isaacs WB, Bova GS, Sidransky D. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 1997; 57: 4997-5000.
29. Lees JR, Charbonneau B, Hayball JD, Diener K, Brown M, Matusik R, Cohen MB, Ratliff TL. Tcell recognition of a prostate specific antigen is not sufficient to induce prostate tissue destruction. Prostate 2006; 66: 578-590.
30. 6 inhibits tumor progression in vivo by a transforming growth factor-β-regulated mechanism. Cancer Res 2008; 68: 561-570.
31. 6 monoclonal antibodies: distinct ligand-mimetic and nonligandmimetic classes. J Biol Chem 2004; 279: 17875-17887.
32. Fornaro M, Tallini G, Zheng DQ, Flanagan WM, Manzotti M, Languino LR. P27(kip1) acts as a downstream effector of and is coexpressed with the β1C integrin in prostatic adenocarcinoma. J Clin Invest 1999; 103: 321-329.
33. 6 integrin regulates renal fibrosis and inflammation in Alport mouse. Am J Pathol 2007; 170: 110-125.
34. Azare J, Leslie K, Al-Ahmadie H, Gerald W, Weinreb PH, Violette SM, Bromberg J. Constitutively activated Stat3 induces tumorigenesis and enhances cell motility of prostate epithelial cells through integrin β6. Mol Cell Bio 2007; 27: 4444-4453.
35. Wen Y, Hu MC, Makino K, Spohn B, Bartholomeusz G, Yan DH, Hung MC. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 2000; 60: 6841-6845.
36. Kirschenbaum A, Liu X, Yao S, Levine AC. The role of cyclooxygenase-2 in prostate cancer. Urology 2001; 58: 127-131.
37. Uotila P, Valve E, Martikainen P, Nevalainen M, Nurmi M, Harkonen P. Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer. Urol Res 2001; 29: 23-28.
38. Madaan S, Abel PD, Chaudhary KS, Hewitt R, Stott MA, Stamp GW, Lalani EN. Cytoplasmic induction and over-expression of cyclooxygenase-2 in human prostate cancer: implications for prevention and treatment. BJU Int 2000; 86: 736-741.
39. Lee MV, Fong EM, Singer FR, Guenette RS. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 2001; 61: 2602-2608.
40. Yoshimura R, Sano H, Masuda C, Kawamura M, Tsubouchi Y, Chargui J, Yoshimura N, Hla T, Wada S. Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 2000; 89: 589-596.
41. Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 2000; 42: 73-78.
42. Zha S, Gage WR, Sauvageot J, Saria EA, Putzi MJ, Ewing CM, Faith DA, Nelson WG, De Marzo AM, Isaacs WB. Cyclooxygenase-2 is upregulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res 2001; 61: 8617-8623.
43. Cheng I, Liu X, Plummer SJ, Krumroy LM, Casey G, Witte JS. COX2 genetic variation, NSAIDs, and advanced prostate cancer risk. Br J Cancer 2007; 97: 557-561.
44. 6 integrin-dependent oral squamous carcinoma invasion. Cancer Res 2006; 66: 10833-10842.
45. Palapattu GS, Sutcliffe S, Bastian PJ, Platz EA, De Marzo AM, Isaacs WB, Nelson WG. Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis 2005; 26: 1170-1181.
46. 6 binds and activates latent TGFβ1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 1999; 96: 319-328.
47. Kehrl JH, Wakefield LM, Roberts AB, Jakowlew S, Alvarez-Mon M, Derynck R, Sporn MB, Fauci AS. Production of transforming growth factor β by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med 1986; 163: 1037-1050.
48. Sheppard D. Integrin-mediated activation of latent transforming growth factor β. Cancer Metastasis Rev 2005; 24: 395-402.
49. Akhurst RJ, Derynck R. TGF-β signaling in cancer-a double-edged sword. Trends Cell Biol 2001; 11: S44-51.